Susceptibility of Helicobacter pylori to Ten Antimicrobial Agents

1996 ◽  
pp. 369-370
Author(s):  
Yakut Akyon ◽  
Gulsen Hascelik ◽  
K. Serdar Diker
Keyword(s):  
Helicobacter Pylori ◽  
Antimicrobial Agents

Eradication of Helicobacter pylori: the power of nanosized formulations

Nanomedicine ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. 527-542
Author(s):  
Qianyu Zhang ◽  
Wen Wu ◽  
Jinqiang Zhang ◽  
Xuefeng Xia
Keyword(s):  
Helicobacter Pylori ◽  
Antibiotic Resistance ◽  
Peptic Ulcer ◽  
Gastric Carcinoma ◽  
Antibacterial Agents ◽  
Antimicrobial Agents ◽  
Mucosal Barrier ◽  
Harsh Environment ◽  
H Pylori ◽  
Cure Rates

Helicobacter pylori is a pathogen that is considered to cause several gastric disorders such as chronic gastritis, peptic ulcer and even gastric carcinoma. The current therapeutic regimens mainly constitute of a combination of several antimicrobial agents and proton pump inhibitors. However, the prevalence of antibiotic resistance has been significantly lowering the cure rates over the years. Nanocarriers possess unique strengths in this regard owing to the fact that they can protect the drugs (such as antibiotics) from the harsh environment in the stomach, penetrate the mucosal barrier and deliver drugs to the desired site. In this review we summarized recent studies of different antibacterial agents orally delivered by nanosized carriers for the eradication of H. pylori.

scholarly journals Helicobacter pylori: Primary Susceptibility to Clarithromycin in vitro in Nova Scotia

1997 ◽  
Vol 11 (4) ◽  
pp. 298-300 ◽  
Author(s):  
Linda M Best ◽  
David JM Haldane ◽  
Gregory S Bezanson ◽  
Sander JO Veldhuyzen
Keyword(s):  
Helicobacter Pylori ◽  
Nova Scotia ◽  
Antimicrobial Agents ◽  
Primary Resistance ◽  
Susceptibility Data ◽  
Mueller Hinton ◽  
Agar Diffusion Test ◽  
Mueller Hinton Agar ◽  
H Pylori

Resistance to antimicrobial agents is a major determinant of the efficacy of regimens to eradicateHelicobacter pylori. Clarithromycin (CLA) has become one of the most commonly used antibiotics for treatment ofH pyloriinfection. In this study, the rate of primary resistance to CLA inH pyloriisolated from patients was determined. One hundred sixty-two strains were recovered from patients before treatment. Strains were grown and inoculated onto Mueller-Hinton agar with 7% sheep blood. CLA epsilometer gradient agar diffusion test (E test) strips were used to test for susceptibility. Appropriate control organisms were tested to validate the assay. Plates were incubated at 37°C in a microaerophilic atmosphere for up to five days. E test results were easy to interpret. Strains were considered resistant if the minimum inhibitory concentration (MIC) was 2 µg/mL or greater. Three strains were resistant (two strains with MIC 8 µg/mL and one strain with MIC 12 µg/mL), and 159 strains were sensitive (MICs ranged from less than 0.016 to 0.38 µg/mL). Ninety per cent of the strains had MICs of 0.023 µg/mL. Primary resistance was 1.8%. These susceptibility data support the use of CLA for the treatment ofH pyloriin the Nova Scotia population.

scholarly journals Helicobacter pylori Eradication Therapy: Current Availabilities

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
M. Gasparetto ◽  
M. Pescarin ◽  
G. Guariso
Keyword(s):  
Helicobacter Pylori ◽  
Eradication Rate ◽  
Antimicrobial Agents ◽  
Eradication Therapy ◽  
Sequential Therapy ◽  
Industrialized Countries ◽  
Quadruple Therapy ◽  
Medline Search ◽  
Meta Analyses ◽  
Resistance Rates

Background. Though Helicobacter pylori (HP) infections have progressively declined throughout most of the industrialized countries, a gradual increase in failure of HP eradication treatments is observed. Aim. To critically review evidence on the efficacy of the therapeutic availabilities for HP eradication, as yet. Methods. A selection of Clinical Trials, Systematic Reviews and Meta-analyses within the time period 2010–2012, was performed through a Medline search. Previous references were included when basically supporting the first selection. Results. An increasing rise in HP resistance rates for antimicrobial agents is currently observed. Further causes of HP treatment failure include polymorphisms of the CYP 2C19, an increased body mass index (BMI), smoking, poor compliance and re-infections. Alternative recent approaches to standard triple therapy have been attempted to increase the eradication rate, including bismuth-containing quadruple therapy, non-bismuth containing quadruple therapy, sequential therapy and levofloxacin-containing regimens. Conclusions. The main current aims should be the maintenance of a high eradication rate (>85%) of HP and the prevention of any increase in antimicrobial resistance. In the next future, the perspective of a tailored therapy could optimize eradication regimens within the different countries.

scholarly journals Effect of anti-ulcer terpenes and some antimicrobial agents on the growth of Helicobacter pylori.

Ensho ◽  
1992 ◽  
Vol 12 (4) ◽  
pp. 343-347
Author(s):  
Shinichi Narikawa ◽  
Akira Yanagawa ◽  
Seiji Hori ◽  
Jingoro Shimada ◽  
Yutaka Mizushima
Keyword(s):  
Helicobacter Pylori ◽  
Antimicrobial Agents

scholarly journals Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria

2000 ◽  
Vol 49 (5) ◽  
pp. 415-418 ◽  
Author(s):  
LUDMILA BOYANOVA ◽  
IRINA STANCHEVA ◽  
ZOYA SPASSOVA ◽  
NIKOLAI KATZAROV ◽  
IVAN MITOV ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Antimicrobial Agents

scholarly journals Antibody to Heat Shock Protein Can Be Used for Early Serological Monitoring of Helicobacter pylori Eradication Treatment

2000 ◽  
Vol 7 (4) ◽  
pp. 574-577 ◽  
Author(s):  
Naoko Yunoki ◽  
Kenji Yokota ◽  
Motowo Mizuno ◽  
Yoshiro Kawahara ◽  
Masayasu Adachi ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Heat Shock ◽  
Antimicrobial Agents ◽  
Eradication Therapy ◽  
Enzyme Linked Immunosorbent Assay ◽  
Peptic Ulcers ◽  
Whole Cell ◽  
Humoral Immune ◽  
Whole Cell Lysate ◽  
H Pylori

ABSTRACT Infection with Helicobacter pylori induces humoral immune responses against various antigens of the bacterium. Heat shock proteins (hsps) are immunodominant antigens in various diseases including H. pylori infection. In the present study, we measured the anti-hsp antibody titers in 42 patients with H. pylori-infected peptic ulcers during a bacterial eradication study. The patients were treated with a proton pump inhibitor and antimicrobial agents to eradicate the organism. Their sera were obtained at pretreatment and at 1 month and 6 months after the eradication therapy. The titers of immunoglobulin G antibodies to theH. pylori hsp, whole-cell lysate, and urease (30-kDa subunit) antigens in serum were measured by a capture enzyme-linked immunosorbent assay. The levels of H. pylori hsp60 antibodies in sera collected 1 month after treatment had declined significantly, even when changes in the titers of antibodies to whole-cell and urease antigens were not apparent. These results suggest that measurement of antibodies to H. pylorihsp60 in serum is useful for the early monitoring of the effectiveness of eradication therapy.

Sign in / Sign up

Export Citation Format

Share Document